Last reviewed · How we verify
SAR125844
At a glance
| Generic name | SAR125844 |
|---|---|
| Sponsor | Sanofi |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study of SAR125844 Single Agent Administered as Slow Intravenous Infusion in Adult Patients With Advanced Malignant Solid Tumors (PHASE1)
- A Study Assessing Efficacy and Safety of SAR125844 in NSCLC Patients With MET Amplification (PHASE2)
- Phase I, Dose Escalation of SAR125844 in Asian Solid Tumor Patients (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SAR125844 CI brief — competitive landscape report
- SAR125844 updates RSS · CI watch RSS
- Sanofi portfolio CI